Novel. Prevalent. Actionable.

We are advancing a growing pipeline of novel and prevalent therapeutic targets across oncology, neurodegeneration, and other high-need indications, with attributes that enable the next generation of highly efficacious and safe precision medicines.

IN SILICO DISCOVERYEXPERIMENTAL VALIDATIONPRECLINICAL

CNS

ALS: ALS-101

ONCOLOGY

Breast CancerLung CancerMetastatic Colorectal CancerAMLMultiple Myeloma
© 2026 Envisagenics. All rights reserved